Backed by Science

Luminopia™ One is an digital therapeutic developed closely with leading physicians and neuroscientists and builds upon years of published research. Although Luminopia One has not yet been approved by the FDA, several clinical trials conducted on the therapeutic have demonstrated its potential to be an engaging and effective at-home treatment for amblyopia.

Supporting scientific literature

Randomized Controlled Trial of a Dichoptic Digital Therapeutic for Amblyopia

Ophthalmology 2021. In Press.

Digital Therapeutic Improves Visual Acuity and Encourages High Adherence in Amblyopic Children in Open-Label Pilot Study

Journal of AAPOS 2021;25(2):87.e1-87.e6

Improved adherence and treatment outcomes with an engaging, personalized digital therapeutic in amblyopia

Scientific Reports 2020;10:8328.